• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期头颈癌老年患者接受化疗和放疗后的生存及治疗耐受性预测因素

Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer.

作者信息

Bahig Houda, Fortin Bernard, Alizadeh Moein, Lambert Louise, Filion Edith, Guertin Louis, Ayad Tareck, Christopoulos Apostolos, Bissada Eric, Soulières Denis, Gaba Idiamey Francine, Nguyen-Tan Phuc Felix

机构信息

Department of radiation oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Department of radiation oncology, Hopital Maisonneuve Rosemont, Montreal, QC, Canada.

出版信息

Oral Oncol. 2015 May;51(5):521-8. doi: 10.1016/j.oraloncology.2015.02.097. Epub 2015 Mar 18.

DOI:10.1016/j.oraloncology.2015.02.097
PMID:25797461
Abstract

PURPOSE

To report outcomes and predictive factors of overall survival, hospitalization and treatment completion rates in elderly patients with locally advanced head and neck cancer treated with concurrent chemoradiotherapy (CRT).

MATERIAL AND METHODS

A retrospective analysis of patients aged 70years or older treated with concurrent CRT for locally advanced head and neck cancer was conducted. Univariate and multivariate analysis as well as competing risk survival analysis were used to determine predictors of mortality. Logistic regression was used to predict for hospitalization and treatment completion rates.

RESULTS

In total, 129 patients were included. Median follow-up was 27months (range: 1.7-125months). Completion rate of combined CRT was 84%. Actuarial OS and DSS at 4years were 56% and 75%. Hospitalization rate was 36%. On multivariate analysis, a Karnofsky performance status (KPS) ⩽80 was predictive of mortality. Using competing risks, KPS ⩽80 and weight loss >5% were predictive of cancer mortality whereas Charlson score ⩾3 was predictive of mortality due to other causes. On logistic regression, patients with abnormal renal function and lower body mass index were more likely to be hospitalized during their treatment course. Charlson score and chemotherapy regimen were predictive of treatment completion.

CONCLUSION

Concurrent CRT may be a feasible treatment option for healthier older patients at the cost of high hospitalization rates. Pre-treatment factors linked to physiological age such as KPS ⩽80, Charlson score ⩾3, abnormal renal function should be considered at the time of treatment decision.

摘要

目的

报告接受同步放化疗(CRT)的老年局部晚期头颈癌患者的总生存结果、住院率及治疗完成率,并分析预测因素。

材料与方法

对70岁及以上接受同步CRT治疗局部晚期头颈癌的患者进行回顾性分析。采用单因素和多因素分析以及竞争风险生存分析来确定死亡率的预测因素。采用逻辑回归分析预测住院率和治疗完成率。

结果

共纳入129例患者。中位随访时间为27个月(范围:1.7 - 125个月)。同步CRT的完成率为84%。4年的精算总生存率(OS)和无病生存率(DSS)分别为56%和75%。住院率为36%。多因素分析显示,卡氏功能状态评分(KPS)≤80是死亡率的预测因素。采用竞争风险分析,KPS≤80和体重减轻>5%是癌症死亡的预测因素,而查尔森评分≥3是其他原因导致死亡的预测因素。逻辑回归分析显示,肾功能异常和体重指数较低的患者在治疗过程中更易住院。查尔森评分和化疗方案是治疗完成情况的预测因素。

结论

同步CRT对于身体状况较好的老年患者可能是一种可行的治疗选择,但代价是住院率较高。在治疗决策时应考虑与生理年龄相关的预处理因素,如KPS≤80、查尔森评分≥3、肾功能异常。

相似文献

1
Predictive factors of survival and treatment tolerance in older patients treated with chemotherapy and radiotherapy for locally advanced head and neck cancer.局部晚期头颈癌老年患者接受化疗和放疗后的生存及治疗耐受性预测因素
Oral Oncol. 2015 May;51(5):521-8. doi: 10.1016/j.oraloncology.2015.02.097. Epub 2015 Mar 18.
2
Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.≥70岁的局部晚期头颈癌患者接受放化疗后急性死亡率增加。
J Geriatr Oncol. 2017 Jan;8(1):50-55. doi: 10.1016/j.jgo.2016.09.003. Epub 2016 Oct 3.
3
Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer.调强放疗联合同步化疗用于既往接受过放疗的复发性头颈癌
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1067-73. doi: 10.1016/j.ijrobp.2007.04.057.
4
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.局部晚期头颈癌的超分割放疗联合或不联合同步化疗
N Engl J Med. 1998 Jun 18;338(25):1798-804. doi: 10.1056/NEJM199806183382503.
5
Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer.每周和 3 周顺铂同期调强放疗局部晚期头颈部鳞状细胞癌。
Oral Oncol. 2012 Mar;48(3):266-71. doi: 10.1016/j.oraloncology.2011.10.005. Epub 2011 Nov 11.
6
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.局部晚期头颈癌术后放疗联合或不联合同步化疗
N Engl J Med. 2004 May 6;350(19):1945-52. doi: 10.1056/NEJMoa032641.
7
Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.同步西妥昔单抗和放疗在 III 期 NSCLC 患者中:卫星——来自瑞典肺癌研究组的 II 期研究
Lung Cancer. 2011 Feb;71(2):166-72. doi: 10.1016/j.lungcan.2010.05.011. Epub 2010 Jun 11.
8
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer.低剂量每周铂类为基础的放化疗治疗晚期头颈部癌症。
Laryngoscope. 2010 Feb;120(2):236-42. doi: 10.1002/lary.20536.
9
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.诱导化疗改善了接受放化疗后手术的可切除食管癌患者的预后。
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):427-36. doi: 10.1016/j.ijrobp.2004.03.033.
10
Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin.顺铂同期放化疗治疗头颈部癌症时的血液毒性与血清白蛋白水平的关系。
Jpn J Clin Oncol. 2011 Aug;41(8):973-9. doi: 10.1093/jjco/hyr076. Epub 2011 Jun 21.

引用本文的文献

1
Tailoring nonsurgical therapy for elderly patients with head and neck squamous cell carcinoma: A deep learning-based approach.基于深度学习的方法:为老年头颈部鳞状细胞癌患者定制非手术治疗。
Medicine (Baltimore). 2024 Sep 13;103(37):e39659. doi: 10.1097/MD.0000000000039659.
2
Clinicopathological Factors as Predictors for Establishment of Patient Derived Head and Neck Squamous Cell Carcinoma Organoids.临床病理因素作为建立患者来源的头颈部鳞状细胞癌类器官的预测因子。
Head Neck Pathol. 2024 Jun 28;18(1):59. doi: 10.1007/s12105-024-01658-x.
3
Remote Activity Monitoring and Electronic Patient-Reported Outcomes Collection During Radiotherapy for Head and Neck Cancer: A Pilot Study.
头颈部癌症放疗期间的远程活动监测和电子患者报告结局采集:一项试点研究。
JCO Clin Cancer Inform. 2023 Apr;7:e2200132. doi: 10.1200/CCI.22.00132.
4
Evaluation of Concomitant Systemic Treatment in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive Radiotherapy.评估行根治性放疗的老年头颈部鳞状细胞癌患者的系统治疗伴随效应。
JAMA Netw Open. 2023 Feb 1;6(2):e230090. doi: 10.1001/jamanetworkopen.2023.0090.
5
The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients.EBV相关鼻咽癌和HPV相关口咽癌患者年龄与病毒状态之间的相互作用
Cancers (Basel). 2022 Dec 14;14(24):6170. doi: 10.3390/cancers14246170.
6
Poor treatment tolerance in head and neck cancer patients with low muscle mass.肌肉量低的头颈部癌症患者治疗耐受性差。
Head Neck. 2022 Apr;44(4):844-850. doi: 10.1002/hed.26978. Epub 2022 Jan 12.
7
Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.配对分析以评估放疗期间住院作为头颈癌患者生存早期标志物的影响。
Oral Oncol. 2020 Jun 16;109:104854. doi: 10.1016/j.oraloncology.2020.104854.
8
The Multidisciplinary Team (MDT) Approach and Quality of Care.多学科团队(MDT)方法与医疗质量。
Front Oncol. 2020 Mar 20;10:85. doi: 10.3389/fonc.2020.00085. eCollection 2020.
9
Nutritional parameters associated with hospital admissions in patients being treated for head and neck cancer.与头颈部癌症患者住院相关的营养参数。
Support Care Cancer. 2020 Jan;28(1):341-349. doi: 10.1007/s00520-019-04826-w. Epub 2019 May 2.
10
Early Competing Deaths in Locally Advanced Head-and-Neck Cancer.局部晚期头颈癌的早期竞争性死亡
Indian J Palliat Care. 2018 Oct-Dec;24(4):446-450. doi: 10.4103/IJPC.IJPC_91_18.